CNTB Company Profile and Key Details

Q: Who are the executives of CNTB?

Mr. Steven ChanChief Financial OfficerDr. Chin Lee M.D., M.P.H.Chief Medical OfficerMr. Jiang Bian J.D.Gen. Counsel & Chief Compliance OfficerDr. Wubin Pan M.B.A., Ph.D.Co-Founder, Pres & Chairman of DirectorsDr. Raul Collazo Ph.D.Vice President & Global Head of Medical AffairsDr. Lei Sun Ph.D.Vice President of Biologics & Head of CMCDr. Malinda V. Longphre Ph.D.Vice President & Head of US Clinical OperationsDr. Zheng Wei Ph.D.Co-Founder, Chief Executive Officer & Director

NASDAQ : CNTB

Connect Biopharma

$2.19

-0.02-0.90%

Open: 9:54 AM

61.88

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Connect Biopharma Holdings Limited (CNTB) stock declined over -0.90%, trading at $2.19 on NASDAQ, down from the previous close of $2.21. The stock opened at $2.19, fluctuating between $2.17 and $2.21 in the recent session.

Stock Snapshot

2.21

Prev. Close

137.89M

Market Cap

2.1701

Day Low

-3.59

P/E Ratio

-0.61

EPS (TTM)

-570.18

Cash Flow per Share

2.19

Open

62.96M

Number of Shares

2.206

Day High

25.74%

Free Float in %

1834.41

Book Value

12.42K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 21, 2026	2.22	2.24	2.16	2.21	187.98K
Jul 20, 2026	2.34	2.39	2.14	2.20	604.02K
Jul 17, 2026	2.33	2.47	2.31	2.38	380.43K
Jul 16, 2026	2.40	2.44	2.29	2.34	277.91K
Jul 15, 2026	2.36	2.45	2.31	2.43	519.48K
Jul 14, 2026	2.24	2.60	2.22	2.36	1.12M
Jul 13, 2026	2.49	2.49	2.23	2.26	482.77K
Jul 10, 2026	2.60	2.83	2.40	2.51	726.53K
Jul 09, 2026	2.31	2.78	2.27	2.66	2.46M
Jul 08, 2026	2.25	2.32	2.15	2.22	672.24K
Jul 07, 2026	2.36	2.37	2.20	2.21	321.4K
Jul 06, 2026	2.45	2.46	2.30	2.36	366.02K
Jul 02, 2026	2.39	2.50	2.35	2.46	446.79K
Jul 01, 2026	2.45	2.51	2.34	2.39	376.28K
Jun 30, 2026	2.40	2.48	2.37	2.38	591.81K
Jun 29, 2026	2.26	2.40	2.16	2.38	403.14K
Jun 26, 2026	2.12	2.31	2.08	2.19	2.49M
Jun 25, 2026	2.14	2.18	2.05	2.07	167.71K
Jun 24, 2026	2.10	2.18	2.04	2.12	311.67K
Jun 23, 2026	1.94	2.12	1.92	2.09	304.47K

Contact Details

San Diego, CA 215400

United States

https://www.connectbiopharm.com 865 125 3577866

About Company

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

Stock Peers

ARGX

28.55+3.37%

argenx SE$874.74 REGN

3.04+0.45%

Regeneron Pharmaceuticals, Inc.$675.19 MDGL

11.1+2.07%

Madrigal Pharmaceuticals, Inc.$546.79 UTHR

6.49+1.23%

United Therapeutics Corporation$535.83 VRTX

1.5+0.31%

Vertex Pharmaceuticals Incorporated$482.00 KRYS

-0.16-0.05%

Krystal Biotech, Inc.$339.06 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

8.11+2.61%

BeOne Medicines AG$318.69 PRAX

13.44+4.41%

Praxis Precision Medicines, Inc.$317.87 LGND

11.48+3.90%

Ligand Pharmaceuticals Incorporated$305.47

Company Overview

Connect Biopharma Holdings Limited (NASDAQ:CNTB) closed at $2.19 USD, losing -$0.02 (-0.90%) from the previous close of $2.21. The stock is currently mid-range between its 52-week high and low $1.23 and $3.82. With a market capitalization of about $137.89 million, Connect Biopharma Holdings Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.23). Key stats such as the average daily volume over the past year has been around 370.32 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Connect Biopharma Holdings Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Barry D. Quart, the company employs approximately 64 people and listed since March 19, 2021. Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators.

Technical Performance

CNTB has shown sold momentum, gaining 8.49% over the past week and 32.95% over the past quarter, though year-to-date performance is down -18.44%. Short-term trend indicators are bearishly aligned (SMA20 -2.55%, SMA50 1.24%, SMA200 35.07%). The stock’s 14-day RSI is 48.59 (neutral), while the ATR of 0.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.17% below its high and over 394.12% above its low. Average 10-day trading volume of 510.11 thousand shares is slightly above the 3-month average of 378.83 thousand, indicating heightened recent market interest.

Valuation Metrics

Connect Biopharma Holdings Limited trades at a P/E ratio of -4.38, slightly below the S&P 500 average, with a price-to-sales ratio of 2872.73 and a price-to-book ratio of 2.9 suggesting the stock is closer to book value. The P/FCF stands at -5.71, also below market averages.

Dividend & Fair Value

Connect Biopharma Holdings Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.68. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Connect Biopharma Holdings Limited generated EPS of -$0.28 over the past year. Five-year average earnings growth is 7.78%. The latest quarter delivered EPS of -$0.05. The next quarter is forecast at -$0.30. Next year's EPS is expected at $97.80. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $4.00. The high target offers 352.49% upside. The low target suggests 81.0% downside. The mean target is $8.00. This offers 261.99% upside. Connect Biopharma Holdings Limited earnings surprise history is frequent misses against expectations. The quarter that ended May 12, 2026, missed forecasts by -81.75%. The prior quarter beat by -10.0%. Over the last six quarters, Apple has recorded several small beats. These include -133.73% in September 05, 2024.

Shareholding & Insider Activity

Connect Biopharma Holdings Limited has 55.72 million shares outstanding. The public float is 14.34 million shares, elevated short interest at 0.29% of float. This equals 102.42 thousand shares. The short ratio is 0.44 days. Institutional investors hold 81.53% of the float. Insiders own 31.82%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Connect Biopharma has not generated any revenue. Returns are negative, with ROA at -65.77% and ROE at 25.10%.
On valuation metrics, Connect Biopharma trades at a P/E of -4.38, P/S of 2872.73 and P/B of 2.90. The current ratio is 3.74 and quick ratio is 3.74. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 1224.27 days. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -34.55.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2022, Connect Biopharma posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $805.59M (margin 0.0%). Net income was- $797.06M (EPS - $14.50).
The company ended the quarter with $1.13B in cash and short-term investments, a total debt of $3.00M, and net debt of - $547.28M. Total assets were $1.21B, with equity of - $3.18B. Financials further reflected weakness, with operating cash flow of - $47.93M, free cash flow of - $48.22M, and capital expenditures of - $294.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Connect Biopharma Holdings Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.98%, with price expected at $2.32 by August 04, 2026, within a range of $2.19 to $2.47 3-Month Outlook: Projected fall of -48.87%, reaching $1.13 by October 19, 2026, with a range of $1.06 to $1.19. 1-Year Outlook: Projected gain of 678.28%, with price at $17.20 by July 21, 2027, within a range of $17.13 to $17.26.

Key Takeaways

Connect Biopharma Holdings Limited (NASDAQ:CNTB) shares are down -18.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Connect Biopharma Holdings Limited trading at a premium to the broader market with a P/E of -4.38. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $9.12, suggesting 312.67% upside. Our AI forecast model points to short-term strength (4.98% over two weeks), a medium-term fall (-48.87% over three months), and a longer-term gain (678.28% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Connect Biopharma Holdings Limited (CNTB) stock price?

Connect Biopharma Holdings Limited (NASDAQ: CNTB) stock price is $2.19 in the last trading session. During the trading session, CNTB stock reached the peak price of $2.21 while $2.17 was the lowest point it dropped to. The percentage change in CNTB stock occurred in the recent session was -0.9% while the dollar amount for the price change in CNTB stock was - $0.02.

CNTB's industry and sector of operation?

The NASDAQ listed CNTB is part of Biotechnology industry that operates in the broader Healthcare sector. Connect Biopharma Holdings Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CNTB?

Mr. Steven Chan
Chief Financial Officer
Dr. Chin Lee M.D., M.P.H.
Chief Medical Officer
Mr. Jiang Bian J.D.
Gen. Counsel & Chief Compliance Officer
Dr. Wubin Pan M.B.A., Ph.D.
Co-Founder, Pres & Chairman of Directors
Dr. Raul Collazo Ph.D.
Vice President & Global Head of Medical Affairs
Dr. Lei Sun Ph.D.
Vice President of Biologics & Head of CMC
Dr. Malinda V. Longphre Ph.D.
Vice President & Head of US Clinical Operations
Dr. Zheng Wei Ph.D.
Co-Founder, Chief Executive Officer & Director

How CNTB did perform over past 52-week?

CNTB's closing price is 79.67% higher than its 52-week low of $1.23 where as its distance from 52-week high of $3.82 is -42.15%.

How many employees does CNTB have?

Number of CNTB employees currently stands at 64.

Link for CNTB official website?

Official Website of CNTB is: https://www.connectbiopharm.com

How do I contact CNTB?

CNTB could be contacted at phone 865 125 3577866 and can also be accessed through its website. CNTB operates from 3580 Carmel Mountain Road, San Diego, CA 215400, United States.

How many shares of CNTB are traded daily?

CNTB stock volume for the day was 12.42K shares. The average number of CNTB shares traded daily for last 3 months was 370.32K.

What is the market cap of CNTB currently?

The market value of CNTB currently stands at $137.89M with its latest stock price at $2.19 and 62.96M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	64
Beta	-0.23
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CNTB Company Profile and Key Details

Connect Biopharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways